Novo Nordisk says CagriSema cuts weight by 25% in obese women

The headline number matters less than the population behind it: a 25% average in women from a company statement is an efficacy signal, not a full readout, and the absence of comparator data or tolerability detail leaves the competitive picture unresolved. This lands squarely on Novo Nordisk's obesity franchise, where CagriSema is positioned as the successor rather than an addition, so its profile will shape how the company defends its category leadership against rival next-generation candidates. The open question is whether fuller trial disclosure confirms the figure across broader populations and whether the tolerability profile supports the positioning the company is implying.